The historical rank and industry rank for Silence Therapeutics's Net Margin % or its related term are showing as below:
SLN'
s Net Margin % Range Over the Past 10 Years
Min: -15851.88 Med: -594.03 Max: -104.74
Current: -8943.86
SLN's Net Margin % is ranked worse than 92.93% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs SLN: -8943.86
Silence Therapeutics (NAS:SLN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Silence Therapeutics Net Margin % Related Terms
Silence Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Silence Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silence Therapeutics (SLN) has a Net Margin % of -3,544.31% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #880 out of 947 companies in the Biotechnology industry, placing it in the top 92.9%.
Is Silence Therapeutics' Net Margin % too high?
Silence Therapeutics' current Net Margin % is -3,544.31%. Based on the distribution chart, Silence Therapeutics ranks #880 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Silence Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Net Margin % compare to CRBP and TTRX?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #880 out of 947 companies for Net Margin %. This places Silence Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Silence Therapeutics and its competitors. Silence Therapeutics's current Net Margin % is -3,544.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $9.99 — trading 4657.1% above its estimated fair value. The current Net Margin % is -3,544.31%. Silence Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Net Margin % is -3,544.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $9.99 is trading 4657.1% above its estimated GF Value™ of $0.21.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
Net Margin %: -3,544.31%
GF Value™: $0.21 vs. price of $9.99 (4657.1% above fair value)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score
Get the complete analysis for SLN
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
